Report: Harbin syndication falters

The syndication of a $282m leveraged loan connected to a private equity investment in China’s Harbin Pharmaceutical appears to be struggling to attract support.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this